Sharps Technology (NASDAQ:STSS) & GE HealthCare Technologies (NASDAQ:GEHC) Critical Analysis

Sharps Technology (NASDAQ:STSS) and GE HealthCare Technologies (NASDAQ:GEHC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Earnings & Valuation

This table compares Sharps Technology and GE HealthCare Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sharps Technology	N/A	N/A	-$9.30 million	($831.83)	0.00
GE HealthCare Technologies	$20.63 billion	1.59	$2.08 billion	$4.56	15.83

GE HealthCare Technologies has higher revenue and earnings than Sharps Technology. Sharps Technology is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

17.2% of Sharps Technology shares are held by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are held by institutional investors. 1.2% of Sharps Technology shares are held by company insiders. Comparatively, 0.3% of GE HealthCare Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Sharps Technology has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500. Comparatively, GE HealthCare Technologies has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.

Profitability

This table compares Sharps Technology and GE HealthCare Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sharps Technology	N/A	-84.26%	-79.52%
GE HealthCare Technologies	10.11%	21.35%	5.91%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Sharps Technology and GE HealthCare Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sharps Technology	1	0	0	0	1.00
GE HealthCare Technologies	1	6	7	0	2.43

GE HealthCare Technologies has a consensus price target of $92.17, suggesting a potential upside of 27.71%. Given GE HealthCare Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe GE HealthCare Technologies is more favorable than Sharps Technology.

Summary

GE HealthCare Technologies beats Sharps Technology on 11 of the 13 factors compared between the two stocks.

About Sharps Technology

Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.

About GE HealthCare Technologies

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women’s health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women’s health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.